Preclinical studies targeting several enzymes within the NER pathway, including excision repair cross-complementation group 1/xeroderma pigmentosum group F (ERCC1/XPF) and ERCC1/XPA, have demonstrated anti-tumor activity [12,13]. Here, ERCC1 is linked to xeroderma pigmentosum.